Searchable abstracts of presentations at key conferences in endocrinology

ea0044p40 | Adrenal and Steroids | SFEBES2016

Steroid metabolomics for diagnosis of inborn steroidogenic disorders – bridging the gap between clinician and scientist through computational approaches

Baranowski Elizabeth , Bunte Kerstin , Shackleton Cedric , Taylor Angela , Hughes Beverley , Biehl Michael , Tino Peter , Guran Tulay , Arlt Wiebke

Background: The urinary steroid metabolome is considered the fingerprint of adrenal gland function. Novel methods using mass spectrometry profiling have seen the advent of a new era for metabolomics with powerful implications for both diagnostics and discovery. Its interpretation is difficult and performed by few specialists with the expertise to do so. This makes it a relatively inaccessible tool for the majority of Clinical Endocrinologists.Objective: ...

ea0041ep728 | Neuroendocrinology | ECE2016

Women with idiopathic intracranial hypertension have a distinct andro-metabolic signature compared to polycystic ovary syndrome and simple obesity

Kempegowda Punith , O'Reilly Michael , Hornby Catherine , Botfield Hannah , Taylor Angela , Hughes Beverley , Tomlinson Jeremy , Arlt Wiebke , Sinclair Alexandra

Context: Idiopathic intracranial hypertension (IIH) is characterised by elevated intracranial pressure and occurs predominantly in obese premenopausal women. Signs and symptoms of polycystic ovary syndrome (PCOS) often coexist in IIH. Here we compared the androgenic and metabolic phenotypes in IIH, PCOS and simple obesity.Patients and Methods: We studied 25 patients with IIH (mean age 34.4±9.2 years; mean BMI 37.8±5.2 kg/m2), in comp...

ea0038oc1.4 | Early Career Oral Communications | SFEBES2015

Adipose tissue-specific androgen generation fuels an adverse metabolic phenotype in patients with polycystic ovary syndrome

O'Reilly Michael , Kempegowda Punith , Gathercole Laura , Bujalska Iwona , Taylor Angela , Hughes Beverley , Dunn Warwick , Semple Robert , Tomlinson Jeremy , Arlt Wiebke

Insulin resistance and androgen excess are the cardinal features of polycystic ovary syndrome (PCOS). Severity of hyperandrogenism and metabolic dysfunction in PCOS are closely correlated, but underlying mechanisms remain poorly understood. Aldoketoreductase type 1C3 (AKR1C3) is a key source of adipose androgen generation, activating androstenedione to testosterone (T). We postulated that AKR1C3 plays a critical role linking androgen metabolism and metabolic ...

ea0038p193 | Obesity, diabetes, metabolism and cardiovascular | SFEBES2015

Women with idiopathic intracranial hypertension have a distinct andro-metabolic signature compared to polycystic ovary syndrome and simple obesity

O'Reilly Michael , Kempegowda Punith , Botfield Hannah , Ali Fizzah , Taylor Angela , Hughes Beverley , Tomlinson Jeremy , Arlt Wiebke , Sinclair Alex

Context: Idiopathic intracranial hypertension (IIH) is characterised by elevated intracranial pressure and occurs predominantly in obese premenopausal women. Signs and symptoms of polycystic ovary syndrome (PCOS) often coexist in IIH. Here we compared the androgenic and metabolic phenotypes in IIH, PCOS and simple obesity.Patients and methods: We studied 25 patients with IIH (mean age 34.4±9.2 years; mean BMI 37.8±5.2 kg/m2), in comp...

ea0049oc1.3 | Adrenal-Basic & Clinical | ECE2017

Steroid metabolomics for accurate and rapid diagnosis of inborn steroidogenic disorders

Baranowski Elizabeth , Bunte Kerstin , Shackleton Cedric H L , Taylor Angela E , Hughes Beverley A , Biehl Michael , Tino Peter , Guran Tulay , Arlt Wiebke

Background: Urinary steroid metabolite profiling is an accurate reflection of adrenal and gonadal steroid output and metabolism in peripheral target cells of steroid action. Measurement of steroid metabolite excretion by gas chromatography-–mass spectrometry (GC–MS) is considered reference standard for biochemical diagnosis of steroidogenic disorders. However, performance of GC–MS analysis and interpretation of the resulting data requires significant expertise a...

ea0037oc9.2 | Adrenal 2 | ECE2015

Alternative pathway synthesis dominates androgen production in patients with congenital adrenal hyperplasia and is decreased by Chronocort® more than by conventional glucocorticoid therapy

Jones Christopher , Mallappa Ashwini , Reisch Nicole , Hughes Beverley , O'Neil Donna , Krone Nils , Whitaker Martin , Eckland David , Merke Deborah , Ross Richard , Arlt Wiebke

Suppression of excess androgen production poses a considerable clinical challenge in the management of patients with congenital adrenal hyperplasia (CAH). Whilst the major route of androgen synthesis in humans is the classic pathway via androstenedione and testosterone, the relative contribution of the alternative pathway originating from 17-hydroxyprogesterone to androgen excess in CAH has not been defined. Androgen effects of both pathways are elicited in androgen target tis...

ea0037gp.04.01 | Steroids | ECE2015

Dual 5α-reductase inhibition causes hepatic lipid accumulation in man

Hazlehurst Jonathan , Oprescu Andrei , Nikolaou Nikolaos , Grinbergs Annabel , Davies Nigel , Flintham Robert , Hughes Beverley , Taylor Angela , Yu Jinglei , Wagenmakers Anton , Tomlinson Jeremy

5α reductases 1 and 2 (SRD5A1 and SRD5A2) metabolise cortisol into inactive 5α-dihydrocortisol contributing to the regulation of cortisol availability in addition to their established role in the generation of dihydrotestosterone from testosterone. Dutasteride and finasteride are commonly prescribed to patients with benign prostatic hyperplasia but their potential metabolic effects have only recently been identified. Dutasteride inhibits both SRD5A1and SRD5A2 whilst ...